Inozyme Pharma (NASDAQ:INZY) Earns “Outperform” Rating from Wedbush

by · The Markets Daily

Inozyme Pharma (NASDAQ:INZY – Get Free Report)‘s stock had its “outperform” rating reiterated by stock analysts at Wedbush in a research report issued to clients and investors on Friday,RTT News reports. They currently have a $12.00 target price on the stock.

Other research analysts have also recently issued research reports about the stock. Stifel Nicolaus assumed coverage on shares of Inozyme Pharma in a report on Thursday, September 12th. They issued a “buy” rating and a $16.00 price objective for the company. Raymond James began coverage on Inozyme Pharma in a report on Thursday, December 12th. They issued an “outperform” rating and a $26.00 price target for the company. Needham & Company LLC reissued a “buy” rating and issued a $23.00 price objective on shares of Inozyme Pharma in a report on Wednesday, November 6th. Finally, HC Wainwright upped their target price on Inozyme Pharma from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $17.25.

Check Out Our Latest Research Report on INZY

Inozyme Pharma Stock Performance

Shares of INZY stock traded down $0.80 on Friday, hitting $2.00. The company had a trading volume of 2,233,527 shares, compared to its average volume of 817,277. The firm has a market cap of $128.48 million, a P/E ratio of -1.28 and a beta of 1.35. Inozyme Pharma has a twelve month low of $1.97 and a twelve month high of $7.80. The company has a 50-day moving average price of $3.07 and a 200-day moving average price of $4.40. The company has a quick ratio of 7.68, a current ratio of 7.68 and a debt-to-equity ratio of 0.51.

Inozyme Pharma (NASDAQ:INZY – Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.05. As a group, equities research analysts predict that Inozyme Pharma will post -1.59 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Inozyme Pharma

A number of large investors have recently modified their holdings of the business. Bank of New York Mellon Corp grew its position in shares of Inozyme Pharma by 16.1% in the second quarter. Bank of New York Mellon Corp now owns 190,896 shares of the company’s stock valued at $851,000 after purchasing an additional 26,464 shares in the last quarter. Rhumbline Advisers grew its holdings in Inozyme Pharma by 22.0% in the 2nd quarter. Rhumbline Advisers now owns 77,004 shares of the company’s stock valued at $343,000 after buying an additional 13,867 shares in the last quarter. American Century Companies Inc. increased its stake in shares of Inozyme Pharma by 11.0% in the 2nd quarter. American Century Companies Inc. now owns 57,100 shares of the company’s stock worth $255,000 after acquiring an additional 5,673 shares during the last quarter. Meeder Asset Management Inc. purchased a new position in shares of Inozyme Pharma during the 2nd quarter worth $68,000. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Inozyme Pharma by 117.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 380,064 shares of the company’s stock worth $1,695,000 after acquiring an additional 205,417 shares during the period. Hedge funds and other institutional investors own 88.30% of the company’s stock.

Inozyme Pharma Company Profile

(Get Free Report)

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.

Read More